市场调查报告书
商品编码
1400696
全球癌症分析市场评估:按生物标记类型、按技术、按癌症类型、按应用、按最终用户、按地区、机会、预测(2017-2031)Global Cancer Profiling Market Assessment, By Biomarker Type, By Technology, By Cancer Type, By Application, By End-user, By Region, Opportunities and Forecast, 2017-2031F |
全球癌症分析市场规模预计到 2023 年将达到 111.6 亿美元,到 2031 年将达到 225.3 亿美元,2024-2031 年预测期间复合年增长率为 9.18%。市场非常活跃,培育了许多市场公司。随着全球癌症患者数量的增加,预计该市场将大幅成长。
据世界卫生组织称,癌症是全球第二大死因。癌症盛行率的快速增加可归因于基因突变、酒精和烟草的消费、荷尔蒙和生活方式的改变以及致癌微生物感染,这些都是推动全球癌症分析市场的关键因素。针对这一事实,医疗保健专业人士和市场参与者正在专注于开发更先进的解决方案,例如用于准确癌症诊断的癌症分析,以减轻癌症负担。
肿瘤分析使医疗保健专业人员能够根据个人独特的基因图谱开发个人化治疗,从而获得高效的治疗结果。由于人工智慧和机器学习等技术用于癌症诊断和预测,癌症分析市场正在扩大。
癌症是已开发国家和发展中国家的主要原因之一。辐射暴露、饮酒和吸烟以及生活方式的改变是全球癌症患者数量不断增加的主要原因。由于可用于癌症分析和治疗的精确诊断的发展,预计癌症分析市场的成长。在这种情况下,癌症分析对于提供客製化和替代治疗至关重要,这进一步推动了全球癌症分析市场的成长。根据世界卫生组织预测,2025年,新诊断癌症病例数预计将增加约2,162万例,成长率为12.1%。在所有病例中,乳癌是世界上最常见的癌症。乳癌居所有癌症之首,占12%。
透过个人化治疗可以改善癌症治疗的治疗结果。肿瘤和癌症分析是个人化治疗开发的第一步,正在推动市场创新和成长。在基因组技术进步的指导下,这种个人化方法提高了治疗效果,减少了副作用,并改善了患者的治疗结果。癌症分析在临床试验设计中的整合、免疫疗法的日益普及以及政府的支持性举措都有助于在癌症治疗中越来越多地采用个人化医疗。
世界各国政府正在透过宣传活动积极促进癌症筛检和治疗,这推动了全球癌症分析市场的成长。政府资助针对癌症诊断技术的研究计画。2023年3月,美国政府将向三个CDC项目投资3.945亿美元:National Comprehensive Cancer Control Program、National Breast and Cervical Cancer Early Detection Programs、Colorectal Cancer Control Program,以减轻国家的癌症负担。2023年1月,政府宣布将投资1,000万欧元新建29个乳癌筛检设施,以降低英国乳癌的发生率。
COVID-19 大流行对全球癌症分析市场产生了重大影响。癌症患者是最脆弱的人之一。癌症筛检对于癌症控制和预防至关重要,但由于 COVID-19 大流行,许多筛检被取消或推迟,影响了许多患者获得所需护理的机会。COVID-19 导致癌症分析市场中断,对患者、医疗保健专业人员和医疗保健系统产生了巨大影响。根据 2022 年 6 月发表在 SAGE 上的一篇论文,从 2019 年到 2020 年,用于乳癌筛检的乳房 X 光检查减少了 44%。
本报告研究和分析了全球癌症分析市场,提供市场规模和预测、市场动态以及主要参与者的现状和前景。
Global cancer profiling market size was valued at USD 11.16 billion in 2023, expected to reach USD 22.53 billion in 2031, with a CAGR of 9.18% for the forecast period between 2024 and 2031F. The global cancer profiling market is highly dynamic, fostering many market players. The market is expected to grow exponentially due to the increasing number of cancer cases around the world.
As per WHO, cancer is the second leading cause of death globally. The surge in the prevalence of cancer can be attributed to inherited mutations, alcohol and tobacco consumption, hormonal and lifestyle changes, and carcinogenic microbial infections, which play an important role in driving the global cancer profiling market. Owing to this fact, healthcare professionals and market players are focused on developing more advanced solutions like cancer profiling for precise cancer diagnosis to reduce the cancer burden.
Tumor profiling enables healthcare professionals to develop personalized therapy based on unique genetic profiles of individuals, leading to highly effective therapeutic outcomes. The market for cancer profiling is expanding due to the use of technology such as artificial intelligence and machine learning for cancer diagnosis and prediction.
Growing industry partnerships, the introduction of cutting-edge products, and government programs to promote cancer screening are expected to fuel market expansion throughout the projected period. In July 2023, the pioneer in diagnostic information services, Quest Diagnostics, announced the introduction of a new prostate cancer biomarker test via its subspecialty pathology company, AmeriPath, in association with Envision Sciences. The goal of the new tissue-based test service is to assist in meeting the urgent clinical demand for diagnostics that can distinguish between aggressive and less aggressive cases of prostate cancer in men.
Cancer is one of the leading causes of death in developed and developing countries. Exposure to radiation, alcohol and tobacco consumption, and lifestyle changes are the major contributors to the increasing number of cancer patients globally. The market for cancer profiling is expected to grow due to the development of precise diagnostics that can be used to profile and treat cancer. In this case, cancer profiling becomes essential for offering customized treatment alternatives, which further propels the growth of global cancer profiling market. As per WHO, newly diagnosed cancer cases are expected to increase to around 21.62 million with a growth rate of 12.1% by 2025. Among all cases, breast cancer is the world's most prevalent cancer. Breast cancer ranks first among all types of cancer accounting for 12% share.
Improved outcomes in cancer treatments can be achieved by personalized therapy. Tumor or cancer profiling is the preliminary step in the development of personalized therapy, which drives innovation and growth in the market. This personalized approach, guided by advancements in genomic technologies, increases treatment efficacy, reduces adverse effects, and improves patient outcomes. The integration of cancer profiling in clinical trial design, increasing popularity of immunotherapy, and supportive government initiatives contribute to the growing adoption of personalized medicine in cancer care.
In March 2023, Artera invested USD 90 million to customize treatment for prostate cancer. The business will use the money to distribute its ArteraAI Prostate Test and create tests that would enable customized treatment plans for various cancers. By examining the patient's clinical information and biopsy images, Artera's multimodal AI-powered test for prostate cancer patients, known as the ArteraAI Prostate Test, assists in forecasting the possible advantages of treatment and the patient's prognosis.
Governments around the globe are actively pushing cancer screening and therapies through awareness campaigns, which is driving growth in the worldwide cancer profiling market. The government is funding research projects targeting cancer diagnosis techniques. In March 2023, the United States government invested USD 394.5 million in three CDC programs, National Comprehensive Cancer Control Program, National Breast and Cervical Cancer Early Detection Programs, and the Colorectal Cancer Control Program to reduce the cancer burden of the country. In January 2023, to decrease the incidence of breast cancer in the United Kingdom, government announced investment of EUR 10 million to build 29 new breast cancer screening facilities.
The COVID-19 pandemic had a significant impact on the global cancer profiling market. Cancer patients were amongst the most vulnerable populations. Although cancer screening is essential for controlling and prevention of cancer, a large number of screenings were canceled or postponed as a result of the COVID-19 pandemic, affecting a large number of patients for access to necessary medical care. There was large scale impact on patients, medical professionals, and health system from the disruption caused by COVID-19 on cancer profiling market. According to a paper published in SAGE in June 2022, between 2019 and 2020, there was a 44% decrease in breast cancer screening mammography.
Market players are employing a range of strategies to increase their range of solutions offered while giving their customers access to a wide selection of innovative and cutting-edge products. Additionally, companies are expanding the range of diagnostic services they offer to capture a large portion of the market. Many major industry players are using both organic and inorganic growth techniques, like partnerships, mergers and acquisitions, and launch of new products, to strengthen their position in the global market.
In April 2023, Agilent Technologies introduced a CGP test intended for somatic variant profiling. The technique, known as Agilent SureSelect Cancer CGP, decreases hands-on time and increases workflow efficiency to enable scientists to profile a larger variety of tumor samples. The pan-cancer test was developed based on a next-generation sequencing (NGS) panel of 679 genes compiled from cancer databases and research collaborations.
All segments will be provided for all regions and countries covered
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work